Milestone Scientific Pivots from Restructuring to Growth with 400% CompuFlo Sales Target — Milestone Scientific Inc.

Event summary

Milestone Scientific reported a 2.2% Q4 revenue increase to $2.1M, with full-year 2025 revenue up 4% to $9M.
Operating loss improved by 89% in Q4 2025 to $1.1M, driven by cost reductions and financial discipline.
Company targets 10-14% revenue growth in 2026, with CompuFlo sales expected to rise 400%.
Launched dental ambassador program nationally in January 2026 and CompuFlo advisor program in February 2026.
Cash position stood at $1.1M as of December 31, 2025, with $800K in convertible debt outstanding.

The big picture

Milestone Scientific is transitioning from a period of restructuring to growth, focusing on disciplined capital allocation and selective investments in high-ROI initiatives. The company's strategic pivot comes amid broader industry trends toward precision medical devices and digital health solutions. Success will depend on executing its commercialization efforts while maintaining financial discipline.

What we're watching

Revenue Growth Trajectory: Whether Milestone can sustain double-digit revenue growth in 2026, particularly with CompuFlo sales.
Cost Management: The pace at which cost reductions will translate into improved profitability and cash flow breakeven by early 2027.
Market Expansion: How successful the dental ambassador and CompuFlo advisor programs will be in driving adoption and revenue.